SCHEMBL13633844

SCHEMBL13633844

Cc1ccc2cccnc2c1NS(=O)(=O)c1cc(Cl)sc1Cl

nearest known ligand 0.59

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
SLC40A1 Q9NP59 9/20 0.59
MEN1 O00255 4/20 0.53
KMT2A Q03164 4/20 0.53
CDK1 P06493 1/20 0.50
CCNB1 P14635 1/20 0.50
CCNA2 P20248 1/20 0.50
CCND1 P24385 1/20 0.50
CDK2 P24941 1/20 0.50
CDK7 P50613 1/20 0.50
CCNH P51946 1/20 0.50
CCNA1 P78396 1/20 0.50
CDK6 Q00534 1/20 0.50
ATM Q13315 1/20 0.47
MAPT P10636 1/20 0.46
TDP1 Q9NUW8 1/20 0.46
NFKBIA P25963 2/20 0.45
RELA Q04206 2/20 0.45
PKM P14618 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13633878 0.81 SLC40A1 (0.59) SLC40A1MEN1KMT2AATMTDP1
SCHEMBL13633842 0.81 NFKBIA (0.68) SLC40A1MEN1KMT2AMAPTTDP1
SCHEMBL30854814 0.80 SLC40A1 (0.71) SLC40A1MEN1KMT2AATMMAPT
SCHEMBL29255662 0.80 SLC40A1 (0.71) SLC40A1MEN1KMT2AATMMAPT
SCHEMBL2055429 0.78 SLC40A1 (0.72) SLC40A1MEN1KMT2AMAPTTDP1
SCHEMBL11972869 0.75 SLC40A1 (1.00) SLC40A1KMT2AATMMAPTTDP1
SCHEMBL13633824 0.74 SLC40A1 (0.68) SLC40A1MEN1KMT2AMAPTTDP1
SCHEMBL13633855 0.73 NFKBIA (0.67) SLC40A1MEN1KMT2AATMMAPT
SCHEMBL16235754 0.72 TDP1 (0.52) SLC40A1MEN1KMT2ACDK1CCNB1
SCHEMBL13633916 0.71 SLC40A1 (0.72) SLC40A1MEN1KMT2AATMTDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8470821-B2 PDE4B inhibitors and uses therefor PLEXXIKON INC. (US) 2013-06-25 US disclosed
US-8470821-B2 PDE4B inhibitors and uses therefor PLEXXIKON INC. (US) 2013-06-25 US disclosed
US-20090286793-A1 PDE4B INHIBITORS AND USES THEREFOR PLEXXIKON, INC. 2009-11-19 US disclosed
US-20090286793-A1 PDE4B INHIBITORS AND USES THEREFOR PLEXXIKON, INC. 2009-11-19 US disclosed
US-7585859-B2 PDE4B inhibitors and uses therefor PLEXXIKON, INC. (US) 2009-09-08 US disclosed
US-7585859-B2 PDE4B inhibitors and uses therefor PLEXXIKON, INC. (US) 2009-09-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090286793-A1 PDE4B INHIBITORS AND USES THEREFOR PDE4B, PDE7B, PDE4A SLC40A1 4638/4885MEN1 2737/4885KMT2A 2234/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.